A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Condition:   Kita-kyushu Lung Cancer Antigen 1, Human Interventions:   Drug: IL-2 (Aldesleukin);   Drug: Cyclophosphamide;   Biological: KK-LC-1 TCR;   Drug: Fludarabine Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials